These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 18467727

  • 1. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
    Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA.
    J Clin Oncol; 2008 May 10; 26(14):2350-7. PubMed ID: 18467727
    [Abstract] [Full Text] [Related]

  • 2. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
    Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R, Gerogianni A, Cyjon A, Noble J, Laberge F, Chan RT, Fenton D, von Pawel J, Reck M, Shepherd FA, National Cancer Institute of Canada Clinical Trials Group Study BR.21.
    J Clin Oncol; 2006 Aug 20; 24(24):3831-7. PubMed ID: 16921034
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
    Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, Gonzalez EE.
    Lancet Oncol; 2012 Mar 20; 13(3):300-8. PubMed ID: 22277837
    [Abstract] [Full Text] [Related]

  • 4. Erlotinib in previously treated non-small-cell lung cancer.
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L, National Cancer Institute of Canada Clinical Trials Group.
    N Engl J Med; 2005 Jul 14; 353(2):123-32. PubMed ID: 16014882
    [Abstract] [Full Text] [Related]

  • 5. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, Jung SH, Park YH, Ahn JS, Park K, Ahn MJ.
    Lung Cancer; 2012 Jan 14; 75(1):82-8. PubMed ID: 21684626
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.
    Gao H, Ding X, Wei D, Cheng P, Su X, Liu H, Aziz F, Wang D, Zhang T.
    Anticancer Drugs; 2011 Oct 14; 22(9):842-52. PubMed ID: 21808188
    [Abstract] [Full Text] [Related]

  • 7. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
    Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA, TRIBUTE Investigator Group.
    J Clin Oncol; 2005 Sep 01; 23(25):5892-9. PubMed ID: 16043829
    [Abstract] [Full Text] [Related]

  • 8. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
    Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D, Witt K, Botkin D.
    J Clin Oncol; 2008 Feb 20; 26(6):863-9. PubMed ID: 18281658
    [Abstract] [Full Text] [Related]

  • 9. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
    Gaafar RM, Surmont VF, Scagliotti GV, Van Klaveren RJ, Papamichael D, Welch JJ, Hasan B, Torri V, van Meerbeeck JP, EORTC Lung Cancer Group and the Italian Lung Cancer Project.
    Eur J Cancer; 2011 Oct 20; 47(15):2331-40. PubMed ID: 21802939
    [Abstract] [Full Text] [Related]

  • 10. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Spigel DR, Burris HA, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, Whorf RC, Mitchell RB, Daniel DB, Zangmeister J, Bass JD, Hainsworth JD.
    J Clin Oncol; 2011 Jun 20; 29(18):2582-9. PubMed ID: 21576636
    [Abstract] [Full Text] [Related]

  • 11. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
    Bradbury PA, Tu D, Seymour L, Isogai PK, Zhu L, Ng R, Mittmann N, Tsao MS, Evans WK, Shepherd FA, Leighl NB, NCIC Clinical Trials Group Working Group on Economic Analysis.
    J Natl Cancer Inst; 2010 Mar 03; 102(5):298-306. PubMed ID: 20160168
    [Abstract] [Full Text] [Related]

  • 12. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J.
    Clin Ther; 2005 Oct 03; 27(10):1513-34. PubMed ID: 16330289
    [Abstract] [Full Text] [Related]

  • 13. Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer.
    Juhász E, Kim JH, Klingelschmitt G, Walzer S.
    Eur J Cancer; 2013 Apr 03; 49(6):1205-15. PubMed ID: 23477998
    [Abstract] [Full Text] [Related]

  • 14. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
    Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leighl NB, Ho C, Noble J, Lee CW, Seymour L.
    J Clin Oncol; 2010 Jan 01; 28(1):49-55. PubMed ID: 19917841
    [Abstract] [Full Text] [Related]

  • 15. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
    Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, Gobburu J, Booth B, Benson K, Leighton J, Hsieh LS, Chidambaram N, Zimmerman P, Pazdur R.
    Clin Cancer Res; 2005 Sep 15; 11(18):6414-21. PubMed ID: 16166415
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: a retrospective, observational, multicentric study.
    Cioffi P, Marotta V, Fanizza C, Giglioni A, Natoli C, Petrelli F, Grappasonni I.
    J Oncol Pharm Pract; 2013 Sep 15; 19(3):246-53. PubMed ID: 23223401
    [Abstract] [Full Text] [Related]

  • 17. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
    Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, Ibata H, Kozuki T, Endo T, Tamura A, Kamimura M, Sakamoto K, Yoshimi M, Soejima Y, Tomizawa Y, Isa S, Takada M, Saka H, Kubo A.
    J Clin Oncol; 2014 Jun 20; 32(18):1902-8. PubMed ID: 24841974
    [Abstract] [Full Text] [Related]

  • 18. Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
    Kim ST, Lee J, Kim JH, Won YW, Sun JM, Yun J, Park YH, Ahn JS, Park K, Ahn MJ.
    Cancer; 2010 Jun 15; 116(12):3025-33. PubMed ID: 20564408
    [Abstract] [Full Text] [Related]

  • 19. Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer.
    Spigel DR, Lin M, O'Neill V, Hainsworth JD.
    Cancer; 2008 Jun 15; 112(12):2749-55. PubMed ID: 18438878
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer.
    Merimsky O, Cheng CK, Au JS, von Pawel J, Reck M.
    Oncol Rep; 2012 Aug 15; 28(2):721-7. PubMed ID: 22614912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.